Time BioVentures Invests in BillionToOne's $125M Series C Round

Time BioVentures is thrilled to announce its investment in BillionToOne's $125M Series C round, joining co-lead investors Adams Street Partners and Hummingbird Ventures, as well as a syndicate including Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, and Libertus Capital.

BillionToOne, Inc. is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. BillionToOne's molecular counting technology increases the resolution of disease detection using cell-free DNA by over 1000-fold. This technology is at the core of the Company's products. BillionToOne's flagship product, UNITY Screen™, is the only non-invasive prenatal test (NIPT) that can assess fetal risk for common recessive conditions and aneuploidies from one maternal blood sample. According to an independent peer-reviewed publication (Choates et al., 2020), less than half of male partners go through traditional carrier screening when indicated, limiting the identification of at-risk pregnancies. UNITY Screen™ does not require a paternal sample to assess fetal risk, supporting greater equity in care. The Company has been growing its market share at an exponential pace, with test volumes increasing more than 300% year over year in the fiscal year 2021. BillionToOne is applying this same molecular counting technology to a groundbreaking liquid biopsy test that combines treatment selection with monitoring. This test is slated to launch this year.

This Series C funding will be used to expand BillionToOne's commercial and clinical teams, scale-up lab capacity, and conduct clinical studies for their liquid biopsy test. "Our prenatal test is solving a critical unmet medical need. We continue to grow at an incredible rate, and we are building out an ever-increasing set of larger laboratory facilities. The current funding will be used to support our prenatal test growth while launching our differentiated liquid biopsy test that will transform oncology care," said Oguzhan Atay, Ph.D., co-founder, and CEO of BillionToOne.

Original news release: https://www.prnewswire.com/news-releases/billiontoone-closes-125m-series-c-funding-with-premier-global-investors-301513503.html